News | News By Subject | News by Disease News By Date | Search News

Leukemia [Acute lymphocytic leukemia (ALL)] News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Novartis AG (NVS)’ CAR-T Drug Sends 82% of Patients’ Blood Cancer into Remission, Eyes 2017 for Marketing     12/6/2016
As Rival Juno (JUNO) Falters, Kite Pharma (KITE) Touts New CAR-T Data and Maps Out BLA Submission Plans     12/5/2016
FDA Clears Expanded Use of Amgen (AMGN)'s Blincyto     9/2/2016
Juno (JUNO) Halts CAR-T Cancer Trial After Three Patient Deaths     7/11/2016
Novartis AG (NVS) Ponders Over Using a Medical Device-Like Sales Model for Experimental Cancer Therapy     5/17/2016
Juno (JUNO), Five Prime (FPRX) are Quiet Winners at AACR     4/25/2016
Juno (JUNO) Unveils Promising Early Data on Two CAR T Cell Product Candidates     4/21/2016
Novartis AG (NVS)’s Experimental Therapy Wipes Out Blood Cancer in 93 Percent of Patients     12/11/2015
FDA Designates Pfizer (PFE)’s Acute Lymphoblastic Leukemia Drug Breakthrough Status     10/21/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Speedy FDA Approval For Amgen (AMGN)'s Leukemia Immunotherapy BLINCYTO     12/5/2014
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Novartis AG (NVS)'s Leukemia Drug CTL01 Clears Cancer In 90 Percent Of Patients     10/20/2014
Amgen (AMGN)'s Leukemia Drug Blinatumomab Gets FDA Priority Review     10/10/2014

News from Around the Web

Press Releases
Servier And Pfizer (PFE) Announce FDA Clearance Of IND Application For UCART19 In Adult Relapsed/Refractory Acute Lymphoblastic Leukemia     3/9/2017
Amgen (AMGN) Submits Supplemental Biologics License Application For BLINCYTO (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia     2/14/2017
Adaptive Biotech Announces A Collaboration With Amgen (AMGN) To Advance Development Of Clonoseq Assay In Acute Lymphoblastic Leukemia     1/6/2017
Kura Oncology Receives FDA Clearance To Proceed With Clinical Trial For ERK Inhibitor KO-947 And Nominates KO-539 As Development Candidate For Menin-MLL Inhibitor Program     1/4/2017
CTI BioPharma Presents Nonclinical Pharmacology Study Demonstrating Pacritinib Has Distinct Profile Amongst JAK Inhibitors At European Organization for Research and Treatment of Cancer-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium     12/2/2016
Cyclacel Pharma (CYCC)’s Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential In Esophageal Cancer And Acute Leukemia     12/1/2016
ERYtech Pharma Presents New Data On GRASPA’s Mechanism Of Action At American Society of Hematology Annual Meeting     12/1/2016
ERYtech Pharma Withdraws App for GRASPA After the CHMP Calls for More Data     11/15/2016
Amgen (AMGN) Release: BLINCYTO (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia     6/10/2016
GlycoMimetics, Inc. (GLYC)’ GMI-1271 Yields High Remission Rates And Favorable Tolerability In Phase I Portion Of Phase I/II Clinical Trial For AML     6/10/2016
Cantargia Receives Notice Of Allowance From USPTO On IL1RAP In Acute Lymphatic Leukemia     6/8/2016
ASCO2016: Juno (JUNO)’s Investigational CAR T Cell Product Candidate JCAR015 Shows High Response Rates In Adults With B-Cell ALL     6/6/2016
FDA Grants Priority Review For Amgen (AMGN)'s Supplemental Biologics License Application For Blincyto (Blinatumomab)     5/4/2016
Celator Pharma (CPXX) To Report First Quarter 2016 Financial Results On May 10, 2016     5/4/2016
BioSight Completed Treatment Of Patients In Astarabine Phase I/IIa Clinical Trial     4/19/2016

//-->